We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

UTIPRO® PLUS

0

Noventure's Participation in 2018 EAU congress

For the third consecutive year, Noventure has participated in the annual congress of the EAU - European Association of Urology that took place in Copenhagen 17th – 19th March 2018 with about 11,000 participants, coming from 123 countries all over the world. During the Congress 273 scientific sessions included 2,656 presentations of cutting-edge urological updates presented by 1,830 international experts. Noventure participated in this congress with a 28 m2 stand to assess its presence in the urology field thanks to its medical device UTIPRO PLUS intended to control and prevent uncomplicated UTIs.

Read more

Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually.

Thorpe KE, Joski P, Johnston KJ.

Kenneth Thorpe, from Emery University in Atlanta, and his colleagues found in a study carried out in the USA, that while the overall number of bacterial infections remained relatively constant between 2002 and 2014, rising from 13.5 million to 14.3 million annually, the proportion that were antibiotic-resistant rose dramatically, from 5.2% to 11.0%. Patients with antibiotic-resistant infections had spending for bacterial infection that was 165 percent higher than spending by patients without such infections. Sixty-one percent of antibiotic-resistant infections were associated with urinary tract infections. Their conclusion is that the direct costs and the mortality and morbidity attributable to antibiotic-resistant infections make a compelling case for urgent action by national and international policy makers.

Read more

Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview

Núria Piqué, María del Carmen Gómez-Guillén and María Pilar Montero

Disruption of the epithelial barrier function has been recently associated with a variety of diseases, mainly at intestinal level, but also affecting the respiratory epithelium and other mucosal barriers. Non-pharmacological approaches such as xyloglucan, with demonstrated protective barrier properties, are proposed as new alternatives for the management of a wide range of diseases, for which mucosal disruption and, particularly, tight junction alterations, is a common characteristic.

Read more

Let's meet in..

2018, Oct 09

CPhI

Read more

2018, Oct 24

UEG Week 2018

Read more

2018, Nov 26

EuroPLX 68

Read more

2018, Nov 29

PharmaVenue November 2018

Read more